Mitsubishi Chemical's clinical study demonstrates effectiveness of probiotic on intestinal environment
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Subscribe To Our Newsletter & Stay Updated